Treatment of HER2-negative breast cancer in women who have gone through menopause or in men whose cancer worsened during or after certain other treatments.
Treatment of certain types of PIK3CA-related overgrowth spectrum (PROS).
Active constituent: Alpelisib.
Therapeutic effects:
Pivikto 150mg tablet is a kinase inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-alpha.
By blocking the action of enzymes that help cancer cells to grow and multiply, it can reduce cancer growth and spread and help destroy cancer cells.
Interaction with other drugs:
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.
Certain medications interact with Pivikto 150mg tablet and reduce its effectiveness by causing undesirable side effects.
Storage:
Store the Pivikto 150mg tablet at 20°C to 25°C.
Protect the medicine from light and excessive moisture.
Keep the medicine out of reach of children and pets.
How to consume:
Always take this medicine as prescribed by your doctor.
Take the tablet at the same time, immediately after food.
Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.
If you cannot swallow the tablet, mix the tablets into a glass of water as per doctor advice.
Safety advices:
Pregnancy: do not take Pivikto 150mg tablet if you are pregnant because this may harm the unborn baby.
Breastfeeding: breastfeeding is not recommended in patients taking Pivikto 150mg tablet because the medicine passes into the breast milk in small amounts and may harm your baby.
Lungs: consult your doctor if you have any lung diseases before starting the treatment.
Liver: Pivikto 150mg tablet is safe to use in patients with liver problems. There is no need for dose adjustments.
Alcohol: it is not known whether it is safe to consume alcohol with Pivikto 150mg tablet. Please consult your doctor.
Driving: Pivikto 150mg tablet may alter your ability to drive and operate heavy machinery. The treatment may cause tiredness hence avoid activities after taking the medicine.
Your doctor may give you medicines to prevent nausea and vomiting before the treatment.
If you vomit after taking the tablet, take the next dose at the regular time.
Women should use an effective form of birth control during treatment and for 1 week after the last dose.
Male patients who have female partners should use effective birth control during treatment and for 1 week after the last dose.
Tell your doctor if you have kidney disease, lung disease or breathing problems, or diabetes.
Do not breastfeed during treatment with this medicine and for 1 week after the last dose.
Your doctor may advise you to take certain blood tests during the treatment to monitor any unwanted side effects.
FAQs:
Can a patient with kidney problems take Pivikto 150mg tablet?
Pivikto 150mg tablet should be cautiously taken if you have any kidney problems. Dose adjustments are necessary for patients with kidney diseases. Inform your doctor if you are on dialysis and have any kidney disorders.
What if I overdose or take two doses of Pivikto 150mg tablet?
If you unknowingly overdosed or took two doses of Pivikto 150mg tablet, immediately inform your healthcare professional and seek medical advice.
Should Pivikto 150mg tablet be taken with or without food?
Pivikto 150mg tablet comes as a tablet to take by mouth. It is usually taken immediately after the food. Take the tablets as prescribed by your doctor.
Does Pivikto 150mg tablet cause hair loss?
Thinning or loss of your hair will usually start within two to four weeks of your first dose of Pivikto 150mg tablet. You may also have thinning or loss of eyelashes, eyebrows, and other body hair. Consult your doctor if you have excessive hair loss.
Does Pivikto 150mg tablet cause an increase in sugar levels?
Pivikto 150mg tablet is intended to cause hyperglycemia because it blocks the intracellular action of insulin systemically. This mechanism of action creates a transient state of insulin resistance and hyperglycemia, a common adverse event observed.
